2016
DOI: 10.26442/2075-082x_13.4.30-35
|View full text |Cite
|
Sign up to set email alerts
|

Regulatory adaptive status in determining the effectiveness of nebivololum and sotalolum in patients with hypertensive disease and paroxysmal atrial fibrillation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…The decrease in the level of the regulatory and adaptive status during the treatment with a drug from the beta-blocker group (nebivolol) is consistent with the data in (Eremina et al 2016). Bisoprolol, carvedilol, and nebivolol were shown to improve the outcomes in randomized controlled trials (RCTs) in heart failure (Ponikowski et al 2016); however, there are no RCTs reporting on the outcomes of treating hypertensive patients with these beta-blockers (Williams et al 2018).…”
Section: Disorders Of Bp Regulation System Mechanisms At the Integratmentioning
confidence: 53%
“…The decrease in the level of the regulatory and adaptive status during the treatment with a drug from the beta-blocker group (nebivolol) is consistent with the data in (Eremina et al 2016). Bisoprolol, carvedilol, and nebivolol were shown to improve the outcomes in randomized controlled trials (RCTs) in heart failure (Ponikowski et al 2016); however, there are no RCTs reporting on the outcomes of treating hypertensive patients with these beta-blockers (Williams et al 2018).…”
Section: Disorders Of Bp Regulation System Mechanisms At the Integratmentioning
confidence: 53%